Head to Head Survey: BioLineRx (BLRX) and Its Competitors
BioLineRx (NASDAQ: BLRX) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare BioLineRx to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.
This is a breakdown of recent recommendations for BioLineRx and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioLineRx currently has a consensus target price of $3.20, indicating a potential upside of 181.94%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.46%. Given BioLineRx’s stronger consensus rating and higher probable upside, equities research analysts plainly believe BioLineRx is more favorable than its competitors.
Volatility and Risk
BioLineRx has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, BioLineRx’s competitors have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.
Insider and Institutional Ownership
32.3% of BioLineRx shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares BioLineRx and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares BioLineRx and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|BioLineRx Competitors||$207.75 million||-$2.17 million||0.64|
BioLineRx’s competitors have higher revenue and earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.
Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.